10x Genomics Inc. (TXG) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, TXG scores 65 out of 100, a letter grade of C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine 13/20 (ROIC -5.7%; FCF yield 1.22%); Whale 13F Flow 17/20 (institutional accumulation and options positioning); Insider Conviction 10/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 12/20 (Beta 1.15; sector sensitivity); and Forensic Balance Sheet 13/20 (Altman Z 25.02; Piotroski F 8/9; Debt/Equity 0.13). For a prospective investor, the profile is split: the strongest pillar is institutional positioning, and the weakest is insider conviction, while the cash engine is held back by negative ROIC and a low FCF yield. The balance sheet metrics in the source are strong on the forensic scores, but the return on invested capital is negative. The valuation tradeoff is that the stock trades at a forward P/E of 24 against negative trailing EPS of -0.33, so upside depends on earnings turning positive rather than on current profitability. The Beta of 1.15 signals above-market sensitivity to broad moves.

10x Genomics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry, per the profile. The source data does not describe its products, customers, or revenue model. Per the SEC financials, the company reported revenue of $642.8M for FY 2025, indicating a revenue-generating operating base. Specific product lines, such as the Atera and Sentira launches referenced in the news wire, are named only as headlines and are not described in detail in the source.

Per the SEC financials, revenue rose from $618.7M (FY 2023) to $642.8M (FY 2025), while operating losses narrowed from $-265.3M to $-61.0M over the same span. Per the market data, the gross margin is 69.1%, the operating margin is -9.5%, and the net margin is -6.8%, with ROIC at -5.7%. Per the Roarable RQD rating, the forensic scores are Altman Z 25.02 and Piotroski F 8/9, and Debt/Equity is 0.13. FY 2025 free cash flow was positive at $130.1M, though the source does not reconcile this against the operating loss.

The news wire contains six items, all related to TXG. Headlines reference a stock price and news page, a Trefis piece questioning whether the stock will return to its old high, an Investing.com piece asking why the stock fell 10% that day, Yahoo Finance coverage of Atera shipments and Sentira, a GuruFocus note citing a GF Value of $18 after a 4.5% gain, and a Seeking Alpha piece titled around Atera and valuation. The only item tagged as a catalyst is the GuruFocus note; the remainder are tagged as market wire. The most concrete product-level catalyst referenced is the start of Atera shipments. The source data does not give the content of these articles beyond their headlines and summaries. The Butterfly Supply-Chain Graph reports no supply chain links and no proprietary signals.

• What is the company's revenue split by product line, and what portion relates to the Atera and Sentira launches referenced in the news wire?
• What drove the -2.47% move in the current session, and what does the Investing.com item attribute the 10% decline to?
• What are the cash balances for FY 2023 and FY 2025, given the source lists these as N/A?
• Why does FY 2025 free cash flow ($130.1M) diverge so sharply from the FY 2025 operating loss ($-61.0M)?
• What is the trailing P/E and EV/EBITDA, which the source marks as unavailable, and how do they compare to the forward P/E of 24?